Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ACADIA Pharmaceuticals Inc. - Common Stock
(NQ:
ACAD
)
21.98
+0.43 (+2.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ACADIA Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Strategic Fit of ACP-101 Promises Future Revenue Growth for Acadia Pharmaceuticals: Analyst
June 14, 2023
Tuesday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for hyperphagia (a false...
Via
Benzinga
11 Analysts Have This to Say About ACADIA Pharmaceuticals
June 14, 2023
Via
Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
June 14, 2023
Via
Benzinga
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
June 13, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA Pharmaceuticals's Return On Capital Employed Insights
May 23, 2023
Via
Benzinga
What 22 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
May 09, 2023
Via
Benzinga
ACADIA Pharmaceuticals's Earnings: A Preview
May 05, 2023
Via
Benzinga
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
June 08, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
3 Penny Stocks That Could Skyrocket in the Next 12 Months
June 07, 2023
Find the top penny stocks to buy, and you can make a fortune. Pick the wrong one and there are also plenty of horrors.
Via
InvestorPlace
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
June 01, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying
May 25, 2023
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
April 14, 2023
Via
Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
March 20, 2023
Via
Benzinga
Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment
March 13, 2023
Via
Benzinga
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 24, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Records 52-Week High Tuesday Morning
May 23, 2023
Via
Investor Brand Network
Top 5 Health Care Stocks That Should Keep You Up At Night
May 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
May 08, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 02, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
April 25, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 20, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher
April 17, 2023
ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else?
Via
Benzinga
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
April 17, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug
March 14, 2023
The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older.
Via
Benzinga
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
March 14, 2023
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on...
Via
Benzinga
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.